193 results on '"de Herder W.W."'
Search Results
2. Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
3. Midgut neuroendocrine tumor patients have a depleted gut microbiome with a discriminative signature
4. Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy
5. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial
6. Diagnosing pancreatic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1 in daily practice
7. Corrigendum to ‘Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study’ [European Journal of Cancer 154 (2021) 246-252] (European Journal of Cancer (2021) 154(246-252) (S0959804921004044), (10.1016/j.ejca.2021.06.029))
8. The possibilities and impossibilities of treating acromegaly 50 years ago illustrated by Diane Arbus, A Jewish Giant at Home with his Parents, 1970
9. 5-HIAA excretion is not associated with bone metabolism in carcinoid syndrome patients
10. Gigantism
11. Corrigendum to “Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
12. Acromegaly Diagnosis
13. Unmet Needs in Appendiceal Neuroendocrine Neoplasms
14. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms
15. ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours
16. Glucagonoma Syndrome
17. Insulinoma
18. Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms
19. Ghrelinoma
20. Successful Localization of Medullary Thyroid Carcinoma and Its Metastases Using CCK-2 Receptor Scintigraphy with99mTc-Demogastrin 2.
21. Hereditary acromegalic gigantism in the family of Roman Emperor Maximinus Thrax
22. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial
23. Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome)
24. Somatostatin Receptors in Pheochromocytoma
25. Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms
26. Recent developments in the diagnosis and therapy of well-differentiated neuroendocrine tumours
27. Melena in a Patient With a Metastasized Neuroendocrine Tumor Answer to: Image 3: Hepatoduodenal Fistula
28. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly
29. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- A nd Perioperative Therapy in Patients with Neuroendocrine Tumors
30. Incidence and prognosis of carcinoid syndrome: hormones or tumour burden?
31. Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework
32. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy
33. Neuroendocrine Tumors: A Multidisciplinary Approach
34. Molecular imaging of pituitary pathology
35. Catecholamine-induced cardiomyopathy in a patient with malignant paraganglioma
36. Energy and metabolic alterations in prediposition to pheochromocytomas and paragangliomas: the so-called Warburg (and more) effect, 15 years on
37. Heroes in endocrinology: Nobel Prizes
38. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas
39. No association of type-O blood with neuroendocrine tumors in multiple endocrine neoplasia type 1
40. Serum neuron-specific enolase level is an independent predictor of overall survival in patients with gastroenteropancreatic neuroendocrine tumors
41. Pituitary insufficiency
42. Ontogeny of iodothyronine deiodinases in human liver
43. Adrenocortical overexpression of gastric inhibitory polypeptide receptor underlies food-dependent Cushing's syndrome
44. Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma
45. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after 177Lu-octreotate
46. Outpatient surgical treatment of primary hyperparathyroidism
47. Neuroendocrine Tumors
48. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: Functional pancreatic endocrine tumor syndromes
49. New therapeutic options for metastatic malignant insulinomas
50. 2.3.12. Clinically nonfunctioning pituitary tumours and gonadotropinomas
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.